Codeine is an opioid, and standard workplace opiate testing is built to catch it. If an employee has taken codeine, whether from a prescription pain reliever, a prescription cough syrup, or in rare cases from certain poppy seed foods, it can trigger a positive result on the opiate (OPI) panel used in most urine drug tests. What confuses people is that codeine does not always show up as itself. Part of it converts inside the body to morphine, so a lab report can list morphine, codeine, or both. This article explains how that happens, what cutoff levels laboratories use, how long codeine is detectable, and how the medical review officer (MRO) process sorts out a legitimate prescription from misuse.
Codeine and the opiate panel
The federal five panel and most standard workplace urine tests screen for the opiate class using an immunoassay that targets codeine and morphine together. Because codeine and morphine are chemically similar and the immunoassay antibody reacts to both, laboratories group them under one initial test cutoff. A specimen that screens positive on the opiate immunoassay is then confirmed with gas chromatography mass spectrometry (GC/MS), which can identify and separately quantify codeine and morphine.
This two step design, screen then confirm, is standard across federally regulated testing and is described in the Department of Transportation's testing procedures at 49 CFR 40.85, which sets the cutoff concentrations laboratories must use for both the initial and confirmatory opiate tests.
Why codeine can confirm as morphine
After codeine is taken, the liver metabolizes a portion of it into morphine through an enzyme pathway (CYP2D6). The rate varies by individual, since people metabolize codeine to morphine at different speeds depending on their enzyme activity. Because of this conversion, a confirmatory GC/MS test on a specimen from someone who took only codeine can show measurable morphine along with codeine. The reverse is not true: pure morphine use, such as from a prescription morphine product, does not metabolize back into codeine. Laboratories and MROs use this one way relationship, along with the ratio and concentration of each compound, to help interpret what substance was actually taken. Background on codeine's metabolism and clinical use is summarized in the NCBI Bookshelf StatPearls chapter on codeine.
HHS and DOT cutoff levels
Federally regulated drug testing programs, including DOT safety sensitive testing, use cutoff concentrations set out in 49 CFR 40.85. For the opiate class covering codeine and morphine, the rule sets the same cutoff for the initial and confirmatory test.
| Test stage | Analyte | Cutoff concentration |
|---|---|---|
| Initial (immunoassay) test | Codeine/Morphine (grouped) | 2000 ng/mL |
| Confirmatory (GC/MS) test | Codeine | 2000 ng/mL |
| Confirmatory (GC/MS) test | Morphine | 2000 ng/mL |
The rule also requires laboratories to report quantitative values for morphine or codeine when the concentration reaches 15,000 ng/mL or above, a higher reporting threshold that helps distinguish very high level results from borderline ones. These specific values are set out in 49 CFR 40.85, and the underlying HHS Mandatory Guidelines that federal cutoffs are drawn from were published in the Federal Register notice on the Mandatory Guidelines for Federal Workplace Drug Testing Programs. Non-DOT workplace programs are not bound by these federal cutoffs and may set their own, so an employer's specific policy and its laboratory's cutoffs always control for a non-federally regulated test.
How the 2000 ng/mL cutoff relates to poppy seeds
The opiate cutoff was raised from an earlier, lower level specifically to reduce false positives tied to poppy seed consumption, since poppy seeds can carry trace amounts of natural codeine and morphine from the poppy plant. The current 2000 ng/mL threshold is high enough that ordinary poppy seed foods rarely push a specimen over the line, though it is not impossible in every circumstance. For a fuller look at how poppy seeds interact with opiate testing, see our related post on poppy seeds and drug test false positives.
Detection window
Codeine is generally detectable in urine for a short window after use, commonly cited in the range of one to a few days depending on dose, frequency of use, hydration, and individual metabolism. Detection time is not fixed and varies by individual and by the specific product taken, so any window should be treated as a general estimate rather than a certainty.
Prescription cough syrups and combination products
Codeine is an ingredient in some prescription cough syrups and in combination pain relievers paired with acetaminophen or an NSAID. Someone taking a codeine containing prescription as directed can test positive on the opiate panel, and that is expected, not a flaw in the test. What matters for employment purposes is documentation. An employee with a current, valid prescription can generally provide that information to the MRO during the verification process, and the MRO factors it into the final result. Employers should never assume a positive opiate screen by itself means illicit use before the MRO review is complete.
The MRO review process
A positive opiate screen from the laboratory is not the final word. A qualified medical review officer reviews the confirmed result, contacts the employee, and asks about any legitimate medical explanation, including current prescriptions. The MRO considers the specific compound identified, the concentration, and the codeine to morphine relationship described above when deciding whether the result is verified positive or should be reported as negative due to a legitimate medical explanation. For a full walkthrough of this process, see our post on the medical review officer process. Employers should never attempt to interpret a lab result on their own or make an employment decision before the MRO has completed verification.
Extended opiate panels versus the standard panel
Standard federal opiate testing targets codeine and morphine, along with 6 acetylmorphine, a heroin specific marker. It does not target hydrocodone, hydromorphone, oxycodone, or oxymorphone, which are semi synthetic opioids with different chemical structures. Many labs offer an expanded opiate or opioid panel that adds these additional analytes with their own separate cutoffs, since a standard opiate immunoassay calibrated to codeine and morphine may not reliably detect them. Employers who want broader opioid coverage, whether for safety sensitive roles or general workplace policy, should confirm with their laboratory or collection provider which specific analytes a given cup or panel actually screens for rather than assuming "opiate panel" and "opioid panel" mean the same thing.
DOT versus non-DOT testing for codeine
DOT regulated safety sensitive employees are tested under 49 CFR Part 40 procedures, which specify the exact cutoffs described above, chain of custody requirements, and mandatory MRO verification for every confirmed positive. Non-DOT employers are not bound by these specific cutoffs or procedures unless they choose to adopt them by policy. A non-DOT program may use a different cutoff, a different panel configuration, or a different review process entirely. Because of this, an employee's specific test result and its handling depend heavily on which type of program administered the test, and employers should be clear in their written policy about which standard applies.
What employers should keep in mind
- A positive opiate screen naming codeine or morphine does not by itself prove illicit drug use. It confirms the substance was present at or above the cutoff.
- Only a qualified MRO can verify a result as positive after reviewing medical explanations, including prescriptions.
- DOT regulated positions must follow 49 CFR Part 40 procedures exactly, including the MRO verification step, before any return to duty or other consequence is considered.
- Non-DOT employers should have a written policy that mirrors sound verification practices, since state laws on drug testing and employment decisions vary.
Frequently asked questions
Does codeine show up on a standard opiate drug test?
Yes. Codeine is part of the opiate class targeted by the immunoassay used in standard urine opiate screens, and it can be confirmed by GC/MS as codeine, morphine, or both.
Why would a codeine positive show up as morphine on the lab report?
The body converts a portion of codeine into morphine during metabolism. A confirmatory test can detect that morphine even when codeine was the only substance taken. Morphine use does not convert into codeine, which helps labs and MROs interpret the source.
What is the federal cutoff level for codeine and morphine?
Under 49 CFR 40.85, the initial test cutoff for the grouped codeine/morphine opiate class is 2000 ng/mL, and the confirmatory cutoff for each of codeine and morphine is also 2000 ng/mL.
Can poppy seeds cause a codeine positive drug test?
Poppy seeds can contain trace natural codeine and morphine, but the 2000 ng/mL federal cutoff was set specifically to reduce false positives from typical poppy seed consumption. It is not a zero risk scenario in every case, but it is uncommon at that cutoff.
Will a prescription cough syrup with codeine cause a positive result?
It can, since codeine in a prescription product is the same active substance the test detects. An employee with a valid, current prescription should disclose it to the medical review officer during verification.
Who decides if a codeine positive is legitimate or a policy violation?
The medical review officer, not the employer or the laboratory alone, makes that determination after reviewing the confirmed lab result and any medical explanation the employee provides.
Employers who need to set up compliant opiate screening can review our drug test cup collection for cups configured to standard opiate cutoffs.
This article is general information, not legal or medical advice. Testing rules vary by program and jurisdiction, and employers should consult qualified counsel and a medical review officer for specific cases.
